ArticleViruses2026
Development of a Recombinant O/CATHAY Topotype Foot-and-Mouth Disease Virus as a Resource for Vaccine Matching and Efficacy Evaluation.
Article in Viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Foot-and-mouth disease virus serotype O remains a global threat, particularly the O/CATHAY topotype in East and Southeast Asia. Because timely access to emerging field isolates can be limited, reverse genetics provides a flexible approach for generating viruses representing selected circulating strains for vaccine matching and efficacy evaluation. Here, we generated O/CATH/APQA-V18 and evaluated its suitability for vaccine assessment in pigs. A contemporary Vietnamese O/CATHAY strain was selected based on viral protein-1 phylogenetic analysis, and its P1 capsid-coding region was incorporated into an O1 Manisa backbone using reverse genetics. The recombinant virus was characterized by real-time reverse transcription polymerase chain reaction, transmission electron microscopy, and sequence analysis. Two-dimensional virus neutralization tests using sera against O/PanAsia-2 and O/Primorsky yielded antigenic relationship values of 0.04 and 0.11, respectively, indicating poor antigenic matching. In vivo, O/CATH/APQA-V18 induced clinical signs in unvaccinated pigs, confirming its infectivity and pathogenicity. Vaccinated pigs had low neutralizing antibody titers against O/CATH/APQA-V18 before challenge, and only 25% were protected. These findings support O/CATH/APQA-V18 as a genetically defined and reproducible experimental virus for vaccine matching and protective efficacy evaluation against contemporary O/CATHAY viruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.